Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an announcement.
Neuren Pharmaceuticals Limited has announced an update on its ongoing share buy-back program, reporting the purchase of 25,511 ordinary fully paid securities on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders and neurodegenerative diseases. The company is listed on the Australian Securities Exchange under the code NEU.
YTD Price Performance: -6.57%
Average Trading Volume: 1,250
Technical Sentiment Signal: Hold
Current Market Cap: $904.2M
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.